These include Darzalex Faspro (daratumumab; Janssen) for multiple myeloma, Herceptin Hylecta (trastuzumab and hyaluronidase-oysk; Genentech) for human epidermal growth factor receptor 2 (HER2)–overexpressing breast cancer, Rituxan Hycela (rituximab and hyaluronidase human; Genentech) for chronic lymphocytic leukemia and non-Hodgkin lymphoma, and Phesgo (pertuzumab, trastuzumab, and hyaluronidase-zzxf; Genentech) for HER2-positive breast cancer. The gene discussed is ERBB2; the disease is non-Hodgkin lymphoma.